Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Short-term Investments: 2022-2024

Historic Short-term Investments for ARS Pharmaceuticals (SPRY) over the last 3 years, with Dec 2024 value amounting to $263.2 million.

  • ARS Pharmaceuticals' Short-term Investments rose 38.60% to $228.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.7 million, marking a year-over-year increase of 38.60%. This contributed to the annual value of $263.2 million for FY2024, which is 67.23% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Short-term Investments stood at $263.2 million, which was up 67.23% from $157.4 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Short-term Investments high stood at $263.2 million for FY2024, and its period low was $63.9 million during FY2022.
  • Over the past 3 years, ARS Pharmaceuticals' median Short-term Investments value was $157.4 million (recorded in 2023), while the average stood at $161.5 million.
  • Data for ARS Pharmaceuticals' Short-term Investments shows a peak YoY spiked of 146.45% (in 2023) over the last 5 years.
  • Over the past 3 years, ARS Pharmaceuticals' Short-term Investments (Yearly) stood at $63.9 million in 2022, then soared by 146.45% to $157.4 million in 2023, then skyrocketed by 67.23% to $263.2 million in 2024.